Insilico Medicine Clarifies Secondary Listing Plans; No Decision on Abu Dhabi Move

Bulletin Express

05/27

Insilico Medicine Cayman TopCo (“Insilico Medicine”) confirmed that, while it routinely reviews post-listing capital options—including the possibility of a secondary listing in other markets such as Abu Dhabi—no definitive decision has been reached to pursue such a listing.

The Board stated it will release further announcements in line with Hong Kong Stock Exchange requirements should any material developments arise. Until then, shareholders and investors are advised to approach trading in the company’s securities with caution.

The voluntary announcement, dated 27 May 2026 and signed by Chairman and CEO Dr. Aleksandrs Zavoronkovs, reiterates that all strategic capital market actions remain under evaluation. The current board comprises two executive directors, three non-executive directors and three independent non-executive directors.

免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。

热议股票

{"basename":"/hans","ssrTDKData":{"titleTemplate":"%s - 老虎证券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎证券,老虎证券开户,老虎券商,老虎证券官网,老虎证券app,tigertrade老虎证券,股票,炒股,新加坡股票交易平台,投资,投资理财","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.itiger.com/hans/news/1194503614"},"companyName":"老虎证券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1194503614\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/1194503614?lang=zh_CN&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-05-27 12:43","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1194503614","market":"us","top_or_hot":-1,"title":"Insilico Medicine Clarifies Secondary Listing Plans; No Decision on Abu Dhabi Move","media":"Bulletin Express","content":"<p>Insilico Medicine Cayman TopCo (“Insilico Medicine”) confirmed that, while it routinely reviews post-listing capital options—including the possibility of a secondary listing in other markets such as Abu Dhabi—no definitive decision has been reached to pursue such a listing.</p>\n<p>The Board stated it will release further announcements in line with Hong Kong Stock Exchange requirements should any material developments arise. Until then, shareholders and investors are advised to approach trading in the company’s securities with caution.</p>\n<p>The voluntary announcement, dated 27 May 2026 and signed by Chairman and CEO Dr. Aleksandrs Zavoronkovs, reiterates that all strategic capital market actions remain under evaluation. The current board comprises two executive directors, three non-executive directors and three independent non-executive directors.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Insilico Medicine Clarifies Secondary Listing Plans; No Decision on Abu Dhabi Move</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nInsilico Medicine Clarifies Secondary Listing Plans; No Decision on Abu Dhabi Move\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1053168898\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/ed558ed0402cbe7d1ef4d150458f2b2e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Bulletin Express </p>\n<p class=\"h-time\">2026-05-27 12:43</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Insilico Medicine Cayman TopCo (“Insilico Medicine”) confirmed that, while it routinely reviews post-listing capital options—including the possibility of a secondary listing in other markets such as Abu Dhabi—no definitive decision has been reached to pursue such a listing.</p>\n<p>The Board stated it will release further announcements in line with Hong Kong Stock Exchange requirements should any material developments arise. Until then, shareholders and investors are advised to approach trading in the company’s securities with caution.</p>\n<p>The voluntary announcement, dated 27 May 2026 and signed by Chairman and CEO Dr. Aleksandrs Zavoronkovs, reiterates that all strategic capital market actions remain under evaluation. The current board comprises two executive directors, three non-executive directors and three independent non-executive directors.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"03696","symbol_name":"英矽智能","start_time":0,"source_url":"","article_id":"1194503614","we_media_id":"1053168898","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1194503614","pubTimestamp":1779856986,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Bulletin Express","introduction":"Full Coverage of HK & US Stock Announcements","home_visible":1,"id":"1053168898","head_image":"https://community-static.tradeup.com/news/ed558ed0402cbe7d1ef4d150458f2b2e"},"summary":"Insilico Medicine Cayman TopCo (“Insilico Medicine”) confirmed that, while it routinely reviews post-listing capital options—including the possibility of a secondary listing in other markets such as...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"03696":"英矽智能"},"translate_title":"英矽智能明确二次上市计划；阿布扎比搬迁尚未做出决定","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"03696":1},"content_text":"Insilico Medicine Cayman TopCo (“Insilico Medicine”) confirmed that, while it routinely reviews post-listing capital options—including the possibility of a secondary listing in other markets such as Abu Dhabi—no definitive decision has been reached to pursue such a listing.\nThe Board stated it will release further announcements in line with Hong Kong Stock Exchange requirements should any material developments arise. Until then, shareholders and investors are advised to approach trading in the company’s securities with caution.\nThe voluntary announcement, dated 27 May 2026 and signed by Chairman and CEO Dr. Aleksandrs Zavoronkovs, reiterates that all strategic capital market actions remain under evaluation. The current board comprises two executive directors, three non-executive directors and three independent non-executive directors.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"0","news_tag":"SGX","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"}}}